{
    "hands_on_practices": [
        {
            "introduction": "A cornerstone of modern drug development is the ability to predict how a new drug will behave in the human body based on laboratory data. This practice bridges the gap between in vitro experiments and in vivo reality. You will use fundamental Michaelis-Menten kinetics derived from a microsomal assay to forecast the hepatic clearance in a human, a process known as in vitro-in vivo extrapolation (IVIVE) . Mastering this quantitative skill is essential for understanding how scientists first estimate the pharmacokinetic profile of novel drug candidates.",
            "id": "4993812",
            "problem": "A new chemical entity is metabolized primarily by the cytochrome P450 (CYP) enzyme system in human liver microsomes. You perform an in vitro experiment at physiological temperature using Human Liver Microsomes (HLM) to characterize its enzyme kinetics. The incubation volume is $1.0$ mL and contains microsomal protein at $0.50$ mg/mL. At varying substrate concentrations, you determine a maximum metabolic rate of product formation (the Michaelis–Menten maximum velocity) equal to $1200$ pmol/min per incubation and a Michaelis constant of $2.0$ $\\mu$M.\n\nUsing only foundational principles of Michaelis–Menten kinetics and a physiologically based liver model that treats the liver as a single, instantaneously mixed compartment (the “well-stirred” model) under steady-state conditions with perfusion by blood, do the following in a logically derived sequence:\n\n- From first principles of Michaelis–Menten kinetics, identify the expression for the intrinsic clearance at substrate concentrations much lower than the Michaelis constant, and use it to compute the intrinsic clearance normalized per milligram of microsomal protein.\n- Scale this microsomal intrinsic clearance to the whole liver on a per kilogram body weight basis using a microsomal protein per gram liver value of $40$ mg/g and a liver weight of $21.0$ g/kg.\n- Treating hepatic blood flow as $21.0$ mL/min/kg and the unbound fraction in blood as $0.020$, apply the well-stirred liver model under steady state to predict the hepatic blood clearance.\n\nMake the following assumptions to ensure scientific realism and clarity: cytochrome P450–mediated metabolism follows Michaelis–Menten kinetics, the unbound fraction in the in vitro incubation is approximately $1$, there is no extrahepatic clearance, and the blood-to-plasma partition is $1$ so that clearances are in blood units.\n\nExpress the final hepatic blood clearance in mL/min/kg. Round your final answer to four significant figures.",
            "solution": "The problem is valid as it is scientifically grounded in established principles of pharmacokinetics, is well-posed with sufficient and consistent data, and is expressed in objective, formalizable language. We will proceed with the solution by following the requested logical sequence.\n\nThe first step is to determine the intrinsic clearance ($CL_{\\text{int}}$) from the provided Michaelis-Menten parameters. The rate of metabolism, $V$, is described by the Michaelis–Menten equation:\n$$V = \\frac{V_{\\text{max}} \\cdot C}{K_m + C}$$\nwhere $V$ is the reaction velocity, $V_{\\text{max}}$ is the maximum velocity, $K_m$ is the Michaelis constant, and $C$ is the substrate concentration.\n\nClearance is defined as the rate of elimination (in this case, the rate of metabolism, $V$) divided by the substrate concentration, $C$:\n$$CL = \\frac{V}{C}$$\nIntrinsic clearance, $CL_{\\text{int}}$, is the clearance at substrate concentrations much lower than the Michaelis constant ($C \\ll K_m$). Under this condition, the Michaelis-Menten equation simplifies because the denominator $K_m + C$ can be approximated as $K_m$:\n$$V \\approx \\frac{V_{\\text{max}} \\cdot C}{K_m} \\quad \\text{for } C \\ll K_m$$\nSubstituting this simplified expression for $V$ into the definition of clearance gives the expression for intrinsic clearance:\n$$CL_{\\text{int}} = \\frac{V}{C} = \\frac{V_{\\text{max}}}{K_m}$$\nThis is the fundamental relationship for intrinsic clearance based on Michaelis-Menten kinetics. We are also given that the unbound fraction in the in vitro incubation, $f_{u,inc}$, is approximately $1$, which means the clearance calculated is the unbound intrinsic clearance, $CL_{\\text{int,u}}$.\n\nNow, we compute the numerical value of the intrinsic clearance for the in vitro incubation. The given parameters are $V_{\\text{max}} = 1200$ pmol/min and $K_m = 2.0$ $\\mu$M. To ensure dimensional consistency, we convert $K_m$ to units of pmol/$\\mu$L:\n$$K_m = 2.0 \\text{ } \\mu\\text{M} = 2.0 \\frac{\\mu\\text{mol}}{\\text{L}} = 2.0 \\frac{10^6 \\text{ pmol}}{10^6 \\text{ } \\mu\\text{L}} = 2.0 \\frac{\\text{pmol}}{\\mu\\text{L}}$$\nThe intrinsic clearance in the incubation volume is:\n$$CL_{\\text{int,inc}} = \\frac{V_{\\text{max}}}{K_m} = \\frac{1200 \\text{ pmol/min}}{2.0 \\text{ pmol/}\\mu\\text{L}} = 600 \\text{ } \\mu\\text{L/min}$$\nThe problem requires this value to be normalized per milligram of microsomal protein. The total amount of protein in the $1.0$ mL incubation is:\n$$\\text{Protein} = 0.50 \\frac{\\text{mg}}{\\text{mL}} \\times 1.0 \\text{ mL} = 0.50 \\text{ mg}$$\nThe normalized microsomal intrinsic clearance, which we will denote as $cl_{\\text{int,u}}$, is:\n$$cl_{\\text{int,u}} = \\frac{CL_{\\text{int,inc}}}{\\text{Protein}} = \\frac{600 \\text{ } \\mu\\text{L/min}}{0.50 \\text{ mg}} = 1200 \\frac{\\mu\\text{L}}{\\text{min} \\cdot \\text{mg}}$$\n\nThe second step is to scale this microsomal intrinsic clearance to the whole liver on a per kilogram body weight basis. This process is known as in vitro-in vivo extrapolation (IVIVE). We use the given scaling factors: microsomal protein per gram of liver (MPPGL) of $40$ mg/g and liver weight per kilogram of body weight of $21.0$ g/kg.\nThe unbound intrinsic clearance for the whole liver, scaled per kg of body weight ($CL_{\\text{int,u,scaled}}$), is calculated as:\n$$CL_{\\text{int,u,scaled}} = cl_{\\text{int,u}} \\times \\text{MPPGL} \\times \\frac{\\text{Liver Weight}}{\\text{Body Weight}}$$\n$$CL_{\\text{int,u,scaled}} = \\left(1200 \\frac{\\mu\\text{L}}{\\text{min} \\cdot \\text{mg protein}}\\right) \\times \\left(40 \\frac{\\text{mg protein}}{\\text{g liver}}\\right) \\times \\left(21.0 \\frac{\\text{g liver}}{\\text{kg body weight}}\\right)$$\n$$CL_{\\text{int,u,scaled}} = 1008000 \\frac{\\mu\\text{L}}{\\text{min} \\cdot \\text{kg}}$$\nTo express this in more conventional units of mL/min/kg, we convert from $\\mu$L to mL ($1$ mL $= 1000$ $\\mu$L):\n$$CL_{\\text{int,u,scaled}} = 1008000 \\frac{\\mu\\text{L}}{\\text{min} \\cdot \\text{kg}} \\times \\frac{1 \\text{ mL}}{1000 \\text{ } \\mu\\text{L}} = 1008 \\frac{\\text{mL}}{\\text{min} \\cdot \\text{kg}}$$\n\nThe third and final step is to predict the hepatic blood clearance, $CL_H$, using the well-stirred liver model. This model relates hepatic clearance to hepatic blood flow ($Q_H$), the unbound fraction in blood ($f_{u,b}$), and the unbound intrinsic clearance ($CL_{\\text{int,u}}$). The equation is:\n$$CL_H = Q_H \\cdot \\frac{f_{u,b} \\cdot CL_{\\text{int,u,scaled}}}{Q_H + f_{u,b} \\cdot CL_{\\text{int,u,scaled}}}$$\nNote that the problem states that the blood-to-plasma partition ratio is $1$, so blood clearance is the relevant metric. We are given the following values:\n$Q_H = 21.0$ mL/min/kg\n$f_{u,b} = 0.020$\n$CL_{\\text{int,u,scaled}} = 1008$ mL/min/kg\n\nFirst, let's compute the product $f_{u,b} \\cdot CL_{\\text{int,u,scaled}}$:\n$$f_{u,b} \\cdot CL_{\\text{int,u,scaled}} = 0.020 \\times 1008 \\frac{\\text{mL}}{\\text{min} \\cdot \\text{kg}} = 20.16 \\frac{\\text{mL}}{\\text{min} \\cdot \\text{kg}}$$\nNow, we substitute all values into the well-stirred model equation:\n$$CL_H = \\left(21.0 \\frac{\\text{mL}}{\\text{min} \\cdot \\text{kg}}\\right) \\cdot \\frac{20.16 \\frac{\\text{mL}}{\\text{min} \\cdot \\text{kg}}}{21.0 \\frac{\\text{mL}}{\\text{min} \\cdot \\text{kg}} + 20.16 \\frac{\\text{mL}}{\\text{min} \\cdot \\text{kg}}}$$\n$$CL_H = 21.0 \\cdot \\frac{20.16}{41.16} \\frac{\\text{mL}}{\\text{min} \\cdot \\text{kg}}$$\n$$CL_H = 21.0 \\cdot 0.4897959... \\frac{\\text{mL}}{\\text{min} \\cdot \\text{kg}}$$\n$$CL_H \\approx 10.285714 \\frac{\\text{mL}}{\\text{min} \\cdot \\text{kg}}$$\nThe problem requires the final answer to be rounded to four significant figures.\n$$CL_H \\approx 10.29 \\frac{\\text{mL}}{\\text{min} \\cdot \\text{kg}}$$\nThis result represents the predicted hepatic blood clearance.",
            "answer": "$$\\boxed{10.29}$$"
        },
        {
            "introduction": "For orally administered drugs, the journey from the gut to the systemic circulation is perilous, with the liver acting as a major metabolic gatekeeper. This exercise focuses on the \"first-pass effect,\" where a fraction of the drug is eliminated before it can exert its effect throughout the body. By calculating the hepatic extraction ratio, you will explore how the interplay between liver blood flow and intrinsic clearance determines a drug's oral bioavailability and see how sensitive this is to changes in enzyme function .",
            "id": "4993780",
            "problem": "A single oral dose of a high-clearance substrate of cytochrome P450 family 3 subfamily A member 4 (CYP3A4) is administered to a healthy adult. Assume the well-stirred hepatic model under steady state and negligible intestinal first-pass extraction. Hepatic blood flow is $Q = 90 \\ \\mathrm{L \\ h^{-1}}$, the unbound fraction in blood is $f_u = 0.10$, and the baseline intrinsic clearance is $CL_{int} = 9000 \\ \\mathrm{L \\ h^{-1}}$. The well-stirred model relates hepatic clearance to blood flow and intrinsic clearance. Starting from conservation of mass across the liver and the well-stirred model, derive an expression for the hepatic extraction ratio $E$ in terms of $Q$, $f_u$, and $CL_{int}$, and use it to compute the baseline $E$. Define hepatic bioavailability $F_h$ as the fraction of drug escaping hepatic first-pass elimination and compute the baseline $F_h$. Now suppose hepatic CYP3A4 expression decreases to $40\\%$ of baseline and that $CL_{int}$ scales proportionally with enzyme expression. Compute the new hepatic extraction ratio and the new hepatic bioavailability. Report, as your final answer, the fold-change in oral bioavailability $F_{new}/F_{old}$ as a unitless decimal, and round your answer to four significant figures.",
            "solution": "The problem requires the derivation of the hepatic extraction ratio, $E$, based on the well-stirred model, and then the calculation of the fold-change in oral bioavailability, $F$, after a reduction in the intrinsic clearance, $CL_{int}$.\n\nFirst, we validate the problem statement.\n**Step 1: Extract Givens**\n- Hepatic blood flow: $Q = 90 \\ \\mathrm{L \\ h^{-1}}$\n- Unbound fraction in blood: $f_u = 0.10$\n- Baseline intrinsic clearance: $CL_{int,old} = 9000 \\ \\mathrm{L \\ h^{-1}}$\n- Model: well-stirred hepatic model at steady state.\n- Condition: Negligible intestinal first-pass extraction.\n- Change in condition: Hepatic CYP3A4 expression decreases to $40\\%$ of baseline.\n- Relation: $CL_{int}$ scales proportionally with enzyme expression.\n- Definition: Hepatic bioavailability $F_h = 1 - E$.\n- Final answer: Fold-change in oral bioavailability $F_{new}/F_{old}$, rounded to four significant figures.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded in standard pharmacokinetic principles (the well-stirred model), uses realistic physiological and drug parameters, and is well-posed with a clear objective. There are no contradictions, ambiguities, or factual unsoundness. The problem is deemed valid.\n\n**Derivation of Hepatic Extraction Ratio, $E$**\nThe rate of drug elimination in the liver can be described from two perspectives.\nFrom a clearance perspective, the rate of elimination is the product of hepatic blood clearance, $CL_h$, and the drug concentration in the blood entering the liver, $C_{in}$:\n$$\n\\text{Rate of elimination} = CL_h \\cdot C_{in}\n$$\nThis rate must equal the net loss of drug from the blood as it perfuses the liver, which is the hepatic blood flow, $Q$, times the difference between entering ($C_{in}$) and exiting ($C_{out}$) concentrations:\n$$\n\\text{Rate of elimination} = Q \\cdot (C_{in} - C_{out})\n$$\nThe hepatic extraction ratio, $E$, is defined as the fraction of drug removed from the blood during its transit through the liver:\n$$\nE = \\frac{C_{in} - C_{out}}{C_{in}}\n$$\nFrom this definition, it follows that $C_{in} - C_{out} = E \\cdot C_{in}$. Substituting this into the rate equation gives $CL_h \\cdot C_{in} = Q \\cdot (E \\cdot C_{in})$, which simplifies to $CL_h = Q \\cdot E$.\n\nThe well-stirred model provides a mechanistic link between clearance and enzymatic activity. It assumes the liver is a single, well-stirred compartment where the rate of elimination is proportional to the unbound drug concentration. This concentration is assumed to be in equilibrium with the unbound concentration in the blood leaving the liver, $C_{out,u}$. The proportionality constant is the intrinsic clearance, $CL_{int}$.\n$$\n\\text{Rate of elimination} = CL_{int} \\cdot C_{out,u}\n$$\nThe unbound concentration $C_{out,u}$ is related to the total concentration $C_{out}$ by the unbound fraction in blood, $f_u$:\n$$\nC_{out,u} = f_u \\cdot C_{out} \\implies \\text{Rate of elimination} = CL_{int} \\cdot f_u \\cdot C_{out}\n$$\nEquating the two expressions for the rate of elimination:\n$$\nQ \\cdot (C_{in} - C_{out}) = CL_{int} \\cdot f_u \\cdot C_{out}\n$$\nTo express this in terms of $E$, we divide by $C_{in}$:\n$$\nQ \\cdot \\left(\\frac{C_{in} - C_{out}}{C_{in}}\\right) = CL_{int} \\cdot f_u \\cdot \\left(\\frac{C_{out}}{C_{in}}\\right)\n$$\nUsing the definitions $E = (C_{in} - C_{out})/C_{in}$ and $C_{out}/C_{in} = 1 - E$:\n$$\nQ \\cdot E = CL_{int} \\cdot f_u \\cdot (1 - E)\n$$\nNow, we solve for $E$:\n$$\nQ \\cdot E = f_u \\cdot CL_{int} - f_u \\cdot CL_{int} \\cdot E\n$$\n$$\nQ \\cdot E + f_u \\cdot CL_{int} \\cdot E = f_u \\cdot CL_{int}\n$$\n$$\nE \\cdot (Q + f_u \\cdot CL_{int}) = f_u \\cdot CL_{int}\n$$\n$$\nE = \\frac{f_u \\cdot CL_{int}}{Q + f_u \\cdot CL_{int}}\n$$\nThis is the required expression for the hepatic extraction ratio.\n\n**Calculation of Baseline Values**\nThe given baseline values are $Q = 90 \\ \\mathrm{L \\ h^{-1}}$, $f_u = 0.10$, and $CL_{int,old} = 9000 \\ \\mathrm{L \\ h^{-1}}$.\nFirst, we calculate the unbound intrinsic clearance term, $f_u \\cdot CL_{int,old}$:\n$$\nf_u \\cdot CL_{int,old} = 0.10 \\cdot 9000 \\ \\mathrm{L \\ h^{-1}} = 900 \\ \\mathrm{L \\ h^{-1}}\n$$\nNow, we compute the baseline hepatic extraction ratio, $E_{old}$:\n$$\nE_{old} = \\frac{f_u \\cdot CL_{int,old}}{Q + f_u \\cdot CL_{int,old}} = \\frac{900}{90 + 900} = \\frac{900}{990} = \\frac{10}{11}\n$$\nThe hepatic bioavailability, $F_h$, is the fraction of drug that escapes first-pass elimination, defined as $F_h = 1 - E$.\nThe baseline hepatic bioavailability, $F_{h,old}$, is:\n$$\nF_{h,old} = 1 - E_{old} = 1 - \\frac{10}{11} = \\frac{1}{11}\n$$\n\n**Calculation of New Values**\nThe intrinsic clearance decreases to $40\\%$ of its baseline value:\n$$\nCL_{int,new} = 0.40 \\cdot CL_{int,old} = 0.40 \\cdot 9000 \\ \\mathrm{L \\ h^{-1}} = 3600 \\ \\mathrm{L \\ h^{-1}}\n$$\nThe parameters $Q$ and $f_u$ are unchanged. The new unbound intrinsic clearance is:\n$$\nf_u \\cdot CL_{int,new} = 0.10 \\cdot 3600 \\ \\mathrm{L \\ h^{-1}} = 360 \\ \\mathrm{L \\ h^{-1}}\n$$\nThe new hepatic extraction ratio, $E_{new}$, is:\n$$\nE_{new} = \\frac{f_u \\cdot CL_{int,new}}{Q + f_u \\cdot CL_{int,new}} = \\frac{360}{90 + 360} = \\frac{360}{450} = \\frac{36}{45} = \\frac{4}{5}\n$$\nThe new hepatic bioavailability, $F_{h,new}$, is:\n$$\nF_{h,new} = 1 - E_{new} = 1 - \\frac{4}{5} = \\frac{1}{5}\n$$\n\n**Calculation of Fold-Change in Oral Bioavailability**\nThe oral bioavailability, $F$, is given by the product of the fraction absorbed from the gut ($f_a$), the fraction escaping intestinal metabolism ($f_g$), and the fraction escaping hepatic metabolism ($F_h$): $F = f_a \\cdot f_g \\cdot F_h$.\nThe problem states that intestinal first-pass extraction is negligible, which means $f_g = 1$. Therefore, $F = f_a \\cdot F_h$.\nWe assume $f_a$ is constant between the two conditions. The fold-change in oral bioavailability is the ratio of the new bioavailability to the old bioavailability:\n$$\n\\frac{F_{new}}{F_{old}} = \\frac{f_a \\cdot F_{h,new}}{f_a \\cdot F_{h,old}} = \\frac{F_{h,new}}{F_{h,old}}\n$$\nSubstituting the calculated values for $F_{h,new}$ and $F_{h,old}$:\n$$\n\\frac{F_{new}}{F_{old}} = \\frac{1/5}{1/11} = \\frac{1}{5} \\cdot \\frac{11}{1} = \\frac{11}{5} = 2.2\n$$\nThe problem requires the answer as a decimal rounded to four significant figures.\n$$\n\\frac{F_{new}}{F_{old}} = 2.200\n$$",
            "answer": "$$\\boxed{2.200}$$"
        },
        {
            "introduction": "The concept of an \"average patient\" is a useful simplification, but the reality is that we all handle drugs differently, largely due to our unique genetic makeup. This exercise delves into the field of pharmacogenomics, providing a hands-on method to predict how a patient's specific CYP2C19 genotype impacts their ability to metabolize a drug. By translating a genetic profile into a quantitative adjustment of enzyme activity, you will perform a calculation that is fundamental to the practice of personalized medicine .",
            "id": "4993845",
            "problem": "A small molecule substrate of Cytochrome P450 (CYP) 2C19 undergoes hepatic elimination under linear (first-order) conditions. Assume that hepatic elimination is dominated by metabolism, the well-stirred conception of hepatic clearance applies, and enzyme catalytic capacity scales linearly with allelic activity. In a reference population with genotype `*1/*1`, the measured unbound intrinsic clearance is $CL_{\\text{int,u,ref}} = 400$ L/h, of which a fraction $fm_{\\text{CYP2C19}} = 0.70$ is mediated by CYP2C19 and the remainder is mediated by other pathways. The fraction unbound in plasma is $f_{u} = 0.12$, and hepatic blood flow is $Q_{h} = 90$ L/h.\n\nFor translating genotype to enzyme activity, assign the following allele function values: $f_{*1} = 1.0$ (normal function), $f_{*2} = 0.0$ (no function), and $f_{*17} = 1.5$ (increased function). Define the genotype activity score as the sum of the two allele function values, and the genotype’s relative activity (to `*1/*1`) as the genotype activity score divided by $2.0$.\n\nFor a patient with CYP2C19 genotype `*2/*17`:\n- Use the above mapping to compute the genotype’s relative activity.\n- Adjust only the CYP2C19-mediated component of $CL_{\\text{int,u}}$ by this relative activity, leaving non-CYP pathways unchanged.\n- From first principles relating hepatic blood flow, unbound drug, and intrinsic clearance, compute the patient’s predicted hepatic clearance.\n\nExpress your final answer in L/h and round to four significant figures.",
            "solution": "The problem is valid as it is scientifically grounded in established pharmacokinetic and pharmacogenomic principles, well-posed with sufficient and consistent data, and objectively formulated.\n\nThe objective is to compute the predicted hepatic clearance ($CL_h$) for a patient with the CYP2C19 genotype `*2/*17`. This will be done in three steps: calculating the patient's relative enzyme activity, determining the patient's specific unbound intrinsic clearance, and finally, calculating the hepatic clearance using the well-stirred model.\n\n**Step 1: Compute the Genotype's Relative Activity (RA)**\n\nThe patient's genotype is CYP2C19 `*2/*17`. The problem provides the allele function values: $f_{*2} = 0.0$ for the no-function allele and $f_{*17} = 1.5$ for the increased-function allele. The genotype activity score is the sum of these two values:\n$$ \\text{Activity Score} = f_{*2} + f_{*17} = 0.0 + 1.5 = 1.5 $$\nThe reference genotype is `*1/*1`, for which the allele function value is $f_{*1} = 1.0$. The reference activity score is thus $1.0 + 1.0 = 2.0$. The patient's relative activity (RA) is the ratio of the patient's activity score to the reference activity score:\n$$ \\text{RA} = \\frac{\\text{Patient Activity Score}}{\\text{Reference Activity Score}} = \\frac{1.5}{2.0} = 0.75 $$\n\n**Step 2: Compute the Patient's Unbound Intrinsic Clearance ($CL_{\\text{int,u,patient}}$)**\n\nThe total unbound intrinsic clearance in the reference population ($CL_{\\text{int,u,ref}}$) is given as $400$ L/h. This clearance is partitioned into a component mediated by CYP2C19 and a component mediated by other pathways. The fraction mediated by CYP2C19 is $fm_{\\text{CYP2C19}} = 0.70$.\n\nFirst, we calculate the clearance components for the reference genotype:\nThe CYP2C19-mediated component is:\n$$ CL_{\\text{int,u,CYP2C19,ref}} = CL_{\\text{int,u,ref}} \\times fm_{\\text{CYP2C19}} = 400 \\, \\text{L/h} \\times 0.70 = 280 \\, \\text{L/h} $$\nThe component from other pathways is:\n$$ CL_{\\text{int,u,other}} = CL_{\\text{int,u,ref}} \\times (1 - fm_{\\text{CYP2C19}}) = 400 \\, \\text{L/h} \\times (1 - 0.70) = 120 \\, \\text{L/h} $$\nFor the patient with genotype `*2/*17`, the CYP2C19-mediated clearance component is scaled by the relative activity (RA), while the contribution from other pathways remains unchanged.\nThe patient's CYP2C19-mediated component is:\n$$ CL_{\\text{int,u,CYP2C19,patient}} = CL_{\\text{int,u,CYP2C19,ref}} \\times \\text{RA} = 280 \\, \\text{L/h} \\times 0.75 = 210 \\, \\text{L/h} $$\nThe patient's total unbound intrinsic clearance is the sum of the adjusted CYP2C19 component and the unchanged 'other' component:\n$$ CL_{\\text{int,u,patient}} = CL_{\\text{int,u,CYP2C19,patient}} + CL_{\\text{int,u,other}} = 210 \\, \\text{L/h} + 120 \\, \\text{L/h} = 330 \\, \\text{L/h} $$\n\n**Step 3: Compute the Patient's Predicted Hepatic Clearance ($CL_{h,patient}$)**\n\nThe problem specifies the use of the well-stirred model for hepatic clearance. The formula for hepatic clearance ($CL_h$) is:\n$$ CL_h = \\frac{Q_h \\cdot f_u \\cdot CL_{\\text{int,u}}}{Q_h + f_u \\cdot CL_{\\text{int,u}}} $$\nwhere $Q_h$ is the hepatic blood flow, $f_u$ is the fraction unbound in plasma, and $CL_{\\text{int,u}}$ is the unbound intrinsic clearance. We are given $Q_h = 90$ L/h and $f_u = 0.12$. We use the patient-specific value $CL_{\\text{int,u,patient}} = 330$ L/h.\n\nFirst, let's calculate the term $f_u \\cdot CL_{\\text{int,u,patient}}$, which represents the patient's total intrinsic clearance ($CL_{\\text{int,patient}}$):\n$$ CL_{\\text{int,patient}} = f_u \\cdot CL_{\\text{int,u,patient}} = 0.12 \\times 330 \\, \\text{L/h} = 39.6 \\, \\text{L/h} $$\nNow, we substitute this value and $Q_h$ into the hepatic clearance equation:\n$$ CL_{h,patient} = \\frac{Q_h \\cdot CL_{\\text{int,patient}}}{Q_h + CL_{\\text{int,patient}}} = \\frac{90 \\, \\text{L/h} \\times 39.6 \\, \\text{L/h}}{90 \\, \\text{L/h} + 39.6 \\, \\text{L/h}} $$\n$$ CL_{h,patient} = \\frac{3564 \\, (\\text{L/h})^{2}}{129.6 \\, \\text{L/h}} = 27.5 \\, \\text{L/h} $$\nThe problem asks for the answer to be expressed in L/h and rounded to four significant figures. To express $27.5$ with four significant figures, we write it as $27.50$.",
            "answer": "$$ \\boxed{27.50} $$"
        }
    ]
}